What is BCRX's health score?

BIOCRYST PHARMACEUTICALS INC (BCRX) has a TradeApes health score of 73 out of 100, rated Healthy. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BCRX's estimated fair value?

Based on our 5-year discounted cash flow model, BIOCRYST PHARMACEUTICALS INC's estimated fair value is $12.82 per share, representing a 51.4% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is BCRX undervalued or overvalued?

Our model currently rates BCRX as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for BCRX... Refresh in a moment for the full analysis.

BIOCRYST PHARMACEUTICALS INC (BCRX)

Healthcare Undervalued low healthy

$8.47

Updated: 2026-06-05

TradeApes Score

Financial Strength

90 Strong

Operating Trend

85 Strong

Relative Value

65 Healthy

Capital Allocation

30 Weak

Risk

80 Strong

Est. Fair Value $12.82

DCF Upside +51.4%

Sector Rank #102 of 6941

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.